Pharmacogenetics of Antipsychotics

Brandl, Eva J.; Kennedy, James L.; Müller, Daniel J.
February 2014
Canadian Journal of Psychiatry;Feb2014, Vol. 59 Issue 2, p76
Academic Journal
Objective: During the past decades, increasing efforts have been invested in studies to unravel the influence of genetic factors on antipsychotic (AP) dosage, treatment response, and occurrence of adverse effects. These studies aimed to improve clinical care by predicting outcome of treatment with APs and thus allowing for individualized treatment strategies. We highlight most important findings obtained through both candidate gene and genome-wide association studies, including pharmacokinetic and pharmacodynamic factors. Methods: We reviewed studies on pharmacogenetics of AP response and adverse effects published on PubMed until early 2012. Owing to the high number of published studies, we focused our review on findings that have been replicated in independent studies or are supported by meta-analyses. Results: Most robust findings were reported for associations between polymorphisms of the cytochrome P450 system, the dopamine and the serotonin transmitter systems, and dosage, treatment response, and adverse effects, such as AP-induced weight gain or tardive dyskinesia. These associations were either detected for specific medications or for classes of APs. Conclusion: First promising and robust results show that pharmacogenetics bear promise for a widespread use in future clinical practice. This will likely be achieved by developing algorithms that will include many genetic variants. However, further investigation is warranted to replicate and validate previous findings, as well as to identify new genetic variants involved in AP response and for replication of existing findings.


Related Articles

  • Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects. Pilgrim, J. L.; Gerostamoulos, D.; Drummer, Olaf H. // Forensic Science, Medicine & Pathology;Jun2011, Vol. 7 Issue 2, p162 

    The field of pharmacogenetics contains a wealth of potential for the enhancement of clinical practice by providing a more effective match between patient and drug, consequently reducing the probability of an adverse drug reaction. Although a relatively novel concept in the forensic context,...

  • Pharmacogenomics Education: International Society of Pharmacogenomics Recommendations for Medical, Pharmaceutical, and Health Schools Deans of Education. Gurwitz, D.; Lunshof, J. E.; Dedoussis, G.; Flordellis, C. S.; Fuhr, U.; Kirchheiner, J.; Licinio, J.; Llerena, A.; Manolopoulos, V. G.; Sheffield, L. J.; Siest, G.; Torricelli, F.; Vasiliou, V.; Wong, S. // Pharmacogenomics Journal;2005, Vol. 5 Issue 4, p221 

    Pharmacogenomics would be instrumental for the realization of personalized medicine in coming decades. Efforts are evident to clarify the potential bioethical, societal, and legal implications of key pharmacogenomics-based technologies projected to be soon introduced into the core practice of...

  • Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening? Laika, B.; Leucht, S.; Heres, S.; Steimer, W. // Pharmacogenomics Journal;Dec2009, Vol. 9 Issue 6, p395 

    The cytochrome P450 2D6 (CYP2D6) isoenzyme metabolizes about 25% of clinically used drugs. The impact of CYP2D6 metabolizer status on therapeutic outcome was assessed in 365 psychiatric in-patients treated with neuroleptics or antidepressants. Length of hospitalization and response onset were...

  • Drug interactions that matter. Brewer, Linda; Williams, David // Africa Health;Mar2013, Vol. 35 Issue 3, p36 

    Drug-drug interactions arise when the effects of one drug are altered by the co-administration of another. The clinical response seen depends on many factors, including individual patient characteristics such as age, co-morbidities and pharmacogenetics. The number of potential drug interactions...

  • Pharmacogenomics- The Promise of Personalized Medicine. Fakruddin, M.; Chowdhury, A. // Bangladesh Journal of Medical Science;Oct2013, Vol. 12 Issue 4, p346 

    Introduction: Pharmacogenomics (PGx) is the study of the genetic basis of variability among individuals in response to drugs. It is the newest discipline of medicine and is becoming a very active area of research, with the pharmaceutical industry gaining experience applying it, integrating it...

  • PHARMACOGENETICS OF VALPROIC ACID AS UNMODIFIED RISK FACTOR OF ADVERSE DRUG REACTIONS. Shnayder, Natalia; Pilugina, Marina; Dmitrenko, Diana; Bochanova, Elena; Shapovalova, Evgenia; Erikalova, Svetlana; Shmatova, Evgenia; Khamraeva, Elvira // Medical & Health Science Journal;Oct2011, Vol. 7 Issue 3, p26 

    The purpose of the research is the assessment of the role of CYP2C9 gene polymorphisms of the isoenzyme 2?9 of cytochrome ?450 of the liver as unmodified risk factor of adverse drug events development in case of intake of an average therapeutic doses of PA drugs at patients with epilepsy and...

  • Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects. Hawcutt, D B; Ghani, A A; Sutton, L; Jorgensen, A; Zhang, E; Murray, M; Michael, H; Peart, I; Smyth, R L; Pirmohamed, M // Pharmacogenomics Journal;Dec2014, Vol. 14 Issue 6, p542 

    Warfarin is used in paediatric populations, but dosing algorithms incorporating pharmacogenetic data have not been developed for children. Previous studies have produced estimates of the effect of polymorphisms in Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase complex subunit 1...

  • Domperidone treatment for gastroparesis: demographic and pharmacogenetic characterization of clinical efficacy and side-effects. Parkman, Henry; Jacobs, Michael; Mishra, Anurag; Hurdle, Jessica; Sachdeva, Priyanka; Gaughan, John; Krynetskiy, Evgeny; Parkman, Henry P; Jacobs, Michael R; Hurdle, Jessica A; Gaughan, John P // Digestive Diseases & Sciences;Jan2011, Vol. 56 Issue 1, p115 

    Background: Domperidone is a useful alternative to metoclopramide for treatment of gastroparesis due to better tolerability. Effectiveness and side-effects from domperidone may be influenced by patient-related factors including polymorphisms in genes encoding drug-metabolizing...

  • Pharmacogenetic-Based Efavirenz Dose Modification: Suggestions for an African Population and the Different CYP2B6 Genotypes. Mukonzo, Jackson K.; Owen, Joel S.; Ogwal-Okeng, Jasper; Kuteesa, Ronald B.; Nanzigu, Sarah; Sewankambo, Nelson; Thabane, Lehana; Gustafsson, Lars L.; Ross, Colin; Aklillu, Eleni // PLoS ONE;Jan2014, Vol. 9 Issue 1, p1 

    Background: Pharmacogenetics contributes to inter-individual variability in pharmacokinetics (PK) of efavirenz (EFV), leading to variations in both efficacy and toxicity. The purpose of this study was to assess the effect of genetic factors on EFV pharmacokinetics, treatment outcomes and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics